Philippe POULETTYDr. Philippe POULETTY, Chairman of the Board of Directors

CEO of Truffle Capital, founder and reference shareholder of DEINOVE

Education: Doctor of Medicine (University Paris VI), immunologist (staff of the Pasteur Institute), Postdoctoral fellow at Stanford University, where in 1987 he published with his colleagues Larry Burg and John Boothroyd a technique for gene amplification now routinely used in laboratories all around the world.

Career: In 1989 founded SangStat, a company specializing in organ transplantation, acquired in 2002 by the American Genzyme for $600 million. Co-founder and CEO of Truffle Capital, a leading European venture capital company which now manages more than €520 million of investment in the sectors of information technology, life sciences and energy.

Patents: Philippe POULETTY is the author of 29 patents and member of the board of directors of 12 European biotechnology and medical device companies. He also founded three biotechnology companies in Europe and the United States.

Mandates & Representations: Honorary President and founder of France Biotech (French association of biotechnology). Former Vice-President of the European Association for the biotechnology industry EuropaBio.

Awards & Distinctions: 1999 laureate of the American Liver Foundation. Chevalier of the Legion of Honor.


Miroslav RADMANPr. Miroslav RADMAN, Member of the Scientific Advisory Board of DEINOVE

Professor at the Faculty of Medicine of the Paris Descartes University, Co-founder of DEINOVE

Education: Studies of biology and physical chemistry at the University of Zagreb. PhD from the Free University of Brussels.

Career: Professor at the Free University of Brussels (1973-1983), Director of Research at CNRS (Institut Jacques Monod, 1983-1998), "Visiting Professor" at NIH (USA, 1989 -1990). Professor at the Paris Descartes University (Faculty of Medicine Necker Children's Hospital) since 1998, where he directs the INSERM Unit 571 "Molecular genetics and evolutionary medicine." Founder of MedILS (Mediterranean Institute for Life Sciences) in Split, Croatia.

Research & Publications: In 1970, Miroslav RADMAN proposed a hypothesis and original paradigm that still dominates the field of DNA repair, according to which mutations and repairs are overall cell response to genotoxic shock, the SOS response.

Demonstration of the molecular mechanism of speciation (SRM) is the other most spectacular discovery of Miroslav RADMAN. He showed that SRM prevents recombination between similar chromosomes and ensures genome stability and the establishment of genetic barriers between species. Inactivation of these barriers in bacteria and in yeast provides a powerful method in the field of evolutionary biotechnology, a source of new biosynthetic activities.

Miroslav RADMAN is also the co-author of discoveries that contribute to the understanding of the molecular mechanisms involved in the evolution of pathogenic bacteria.

Finally, Miroslav RADMAN has solved a 50 year old mystery by revealing the molecular basis of extreme resistance to ionizing radiation and desiccation of the strongest bacteria: Deinococcus radiodurans (Nature 443: 569-573, 2006).

Miroslav RADMAN has published 191 scientific papers cited more than 10,000 times, and is the author of seven patents.

Mandates & Representations: Member of the Intergovernmental Bioethics Committee of UNESCO (2006). Member of the Board of the AXA Research Fund (2007). Scientific Advisor to the Prime Minister of Croatia (since 2004). Co-founder of four start-ups in biotechnology. Member of the American Academy of Arts & Sciences.

Awards & Distinctions: Winner of the 2011 FEMS-Lwoff Prize.